Adeshwar meditex Limited has filed its quarterly compliance disclosure with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The disclosure pertains to the quarter ended March 31, 2026, and was submitted on April 8, 2026.

Regulatory Compliance Details

The company submitted the mandatory disclosure under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation requires companies to report on dematerialisation activities during each quarter through their Registrar and Transfer Agent.

Dematerialisation Activity Report

Bigshare Services Pvt. Ltd., serving as the company's Registrar and Transfer Agent, confirmed that no dematerialisation requests for equity shares were received during the reporting period. The certificate was issued on April 5, 2026, and subsequently forwarded to BSE Limited by the company.

The RTA's certificate specifically stated that no dematerialisation requests for equity shares of Adeshwar Meditex Limited were received during the period from January 1, 2026 to March 31, 2026.

Filing Authorization

The disclosure was signed and submitted by Krishnojirao Nagaraja Rao, Director of Adeshwar Meditex Limited, bearing DIN 07684308. The document was digitally signed on April 8, 2026, at 16:08:05 hours.

Company and RTA Information

Adeshwar Meditex Limited is located at 605, 6th Floor, Plot-99, Niranjan Building, Bhagwan Todi Bal Udyan Marg, Marine Lines Railway Station, Marine Drive, Mumbai - 400002. The company works with Bigshare Services Pvt. Ltd. as its Registrar and Transfer Agent, with the RTA's registered office at Office No S6-2, 6th Floor, Pinnacle Business Park, Andheri (East), Mumbai - 400093.

This quarterly filing demonstrates the company's adherence to SEBI's regulatory framework and maintains transparency in share transfer and dematerialisation processes for stakeholders.

Adeshwar Meditex Limited has filed its mandatory annual disclosure with BSE Limited under SEBI's takeover regulations for the financial year ended March 31, 2026. The disclosure, submitted on April 7, 2026, confirms compliance with regulatory requirements regarding substantial shareholding by promoters.

Regulatory Compliance Declaration

The company's promoters have declared that no encumbrance was created over their shareholdings during the financial year ended March 31, 2026. This declaration was made in accordance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011.

Abhinandan Nagaraja Rao, Whole Time Director with DIN 08677161, confirmed on behalf of all promoters that they, along with persons acting in concert, have not made any encumbrance over shares held directly or indirectly during FY26.

Promoter Shareholding Details

As of March 31, 2026, the promoter shareholding structure shows significant holdings by key management personnel:

Key Personnel and Documentation

The disclosure documents were signed by both Whole Time Directors of the company:

• Krishnojirao Nagaraja Rao (DIN: 07684308) - Whole Time Director
• Abhinandan Nagaraja Rao (DIN: 08677161) - Whole Time Director

The documentation was digitally signed and submitted to BSE Limited's Department of Corporate Services at P.J. Towers, Dalal Street, Fort, Mumbai. The company operates under BSE scrip code 543309.

Corporate Governance Framework

This annual disclosure represents part of Adeshwar Meditex Limited's ongoing compliance with SEBI's substantial acquisition and takeover regulations. The filing ensures transparency in promoter shareholding patterns and adherence to regulatory frameworks governing listed companies in India.

The company's registered address is at Gala 111 Lok Centre, Marol Maroshi Road, Andheri East, Mumbai-400059, Maharashtra, India, where the audit committee also received copies of the disclosure documentation.